IR News


Upsher-Smith Laboratories Completes Acquisition of Two Treatments for Acute Migraine in Adults

Jul. 22. 2019
IR information

Maple Grove, MN – July 20, 2019 – Upsher-Smith Laboratories, LLC (“Upsher-Smith”, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (“Sawai”, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced that it has completed the acquisition of Tosymra (sumatriptan) Nasal Spray 10 mg, and Zembrace® SymTouch® (sumatriptan succinate) Injection 3 mg from Dr. Reddy's Laboratories Limited (“DRL”, Head office: Hyderabad Telangana, India, Co-Chairman and CEO: G.V. Prasad). The products were previously commercialized through DRL’s wholly owned subsidiary, Promius Pharma LLC (“Promius”, Head office: New Jersey, USA, President: Anil Namboodiripad). Both medications are indicated for the acute treatment of migraine with or without aura in adults.

“More than thirty-six million Americans suffer from migraines, and Upsher-Smith is proud to be diversifying our portfolio with two products that can bring pain relief to a significant number of patients suffering from acute migraine,” said Rusty Field, President and CEO, Upsher-Smith. “We will be working diligently to ensure the smooth delivery of Zembrace® SymTouch® to patients, and to prepare for the launch of Tosymra, which we expect to take place toward the end of 2019.”

The addition of Tosymra and Zembrace® SymTouch® rounds out Upsher-Smith’s migraine product portfolio. The Company currently offers Qudexy® XR (topiramate) Extended-Release Capsules, a once-daily treatment for use in the prevention of migraine headache in adults and adolescents 12 years of age and older.

About Sumatriptan Formulations

Tosymra Nasal Spray 10 mg, and Zembrace® SymTouch® Injection 3 mg are indicated for the acute treatment of migraine with or without aura in adults.

About Migraine

Migraine is an inherited, disabling, neurological condition that leads to attacks of head pain, sensitivity to the environment, and other neurological symptoms.1 It is the third most common and the seventh most disabling medical disorder in the world, affecting more than 36 million Americans.1 Treatments for migraine include acute and prophylactic with the majority of patients using acute treatments.2

  1. American Migraine Foundation. Available at: Accessed June 17, 2019.
  2. Decision Resources Group Report, Symphony Migraine Patient Claims Data. 2015. IMS Database.

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.

As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good for the patients they serve. For more information, visit